Advertisement

European Journal of Clinical Pharmacology

, Volume 37, Issue 5, pp 453–457 | Cite as

Effect of felodipine, a new calcium channel antagonist, on platelet function and fibrinolytic activity at rest and after exercise

  • H. Sengeløv
  • K. Winther
Originals

Summary

Fourteen healthy male volunteers (age 21–29 years, mean 23.7 years) were given placebo for 14 days followed immediately by felodipine 5 mg b.d. for a further 14 days. After each period of treatment blood for analysis was taken at rest and after exercise on a cycle ergometer. Platelet aggregation, plasma beta-thromboglobulin (B-TG), platelet factor 4 (PF-4), adrenaline and noradrenaline, and serum thromboxane B2 (TXB2), 6-keto-prostaglandin (F (6-keto-PGF), and euglobulin clot lysis time (ECLT), were measured on each occasion. The ECG, heart rate and blood pressure were monitored during the exercise tests.

After felodipine therapy there was a significant decrease in the plasma level of PF-4 and B-TG at rest. This effect was maintained during exercise. There was no significant change in platelet aggregation, ECLT, TXB2 or 6-keto-PGF at rest or during exercise. Irrespective of therapy, the plasma levels of adrenaline and noradrenaline were increased and the ECLT was decreased when measured immediately after exercise.

Thus, felodipine in modest therapeutic dosage decreases the plasma levels of B-TG and PF-4, indicating an inhibitory effect on platelet on release. The effect also occurred during exercise. Felodipine did not change fibrinolytic activity or the production of TXB2 or 6-keto-PGF.

Key words

felodipine calcium channel blockade exercise platelet function fibrinolytic activity platelet release adverse effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Le Breton GC, Dinerstein RJ, Roth LJ, Feinberg H (1976) Direct evidence for intracellular divalent cation redistribution associated with platelet shape change. Biochem Biophys Res Commun 71: 362–370Google Scholar
  2. 2.
    Feinstein MB, Feikers J, Fraiser C (1976) An analysis of the mechanism of local anesthetic inhibition of platelet aggregation and secretion. J Pharmacol Exp Ther 197: 215–228Google Scholar
  3. 3.
    Ardlie NG (1982) Calcium ions, drug action and platelet function. Pharmacol Ther 18: 249–270Google Scholar
  4. 4.
    Oxholm P, Winther K (1986) Thrombocyte involvement in immune inflammatory reactions. Allergy 41: 1–10Google Scholar
  5. 5.
    Malamet R, Wise RA, Ettinger WH, Wigley FM (1985) Nifedipine in the treatment of Raynaud's phenomenon. Am J Med 78: 602–608Google Scholar
  6. 6.
    Jones CR, Pasanisi F, Elliott HL, Reid JL (1985) Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies. Br J Clin Pharmacol 20: 191–196Google Scholar
  7. 7.
    Johnsson H (1981) Effects by nifedipine on platelet function in vitro and in vivo. Thromb Res 21: 523–528Google Scholar
  8. 8.
    Takahara K, Kuroiwa A, Matsushima T, Nakashima Y, Takasugi M (1985) Effects of nifedipine on platelet function. Am Heart J 109: 4–8Google Scholar
  9. 9.
    Braunwald E (1982) Mechanism of action of calcium-channel-blocking agents. N Engl J Med 307: 1618–1627Google Scholar
  10. 10.
    Boström S-L, Ljung B, Mårdh S, Forsen S, Thulin E (1981) Interaction of the antihypertensive drug felodipine with calmodulin. Nature 292: 777–778Google Scholar
  11. 11.
    McAlpine HM, Walker ID, Davidson JF, Lawrie TDV, Lorimer AR (1985) Acute haemodynamic and platelet effects of felodipine in hypertensive patients. Drugs 29 [Suppl 2]: 161–164Google Scholar
  12. 12.
    Winther K (1987) The effect of beta-blockade on platelet function and fibrinolytic activity. J Cardiovasc Pharmacol 10: 94–98Google Scholar
  13. 13.
    Winther K, Knudsen JB, Jørgensen EO, Eldrup E (1988) Differential effects of timolol and metoprolol on platelet function at rest and during exercise. Eur J Clin Pharmacol 33: 587–592Google Scholar
  14. 14.
    Jürgensen HJ, Dalsgaard-Nielsen J, Kjøller E, Gormsen J (1981) Effect of long-term beta-blockade with alprenolol on platelet function and fibrinolytic activity in patients with coronary heart disease. Eur J Clin Pharmacol 20: 242–250Google Scholar
  15. 15.
    Edgar B, Regårdh CG, Johnsson G, Johansson L, Lundborg P, Löfberg I, Rönn O (1985) Felodipine kinetics in healthy men. Clin Pharmacol Ther 38: 205–211Google Scholar
  16. 16.
    Handin RI, McDonough M, Lesch M (1978) Elevation of platelet factor four in acute myocardial infarction: Measurement by radio-immunoassay. J Lab Clin Med 91: 340–349Google Scholar
  17. 17.
    Ludlam CA, Moore S, Bolton AE, Pepper DS, Cash JD (1975) The release of a human platelet specific protein measured by a radioimmunoassay. Thromb Res 6: 543–548Google Scholar
  18. 18.
    Born GVR (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927–929Google Scholar
  19. 19.
    Demers LM, Derch DD (1980) A radioimmunoassay for 6-ketoprostaglandin F-1-. Adv Prostaglandin Tromboxane Leukotriene Res 6: 193–199Google Scholar
  20. 20.
    Fitzpatrick SA, Gorman RR, McQuire JC, Kelly RC, Wynalda MA, Sun FF (1977) Thromboxane B2. Anal Biochem B2: 1–7Google Scholar
  21. 21.
    Peuler JD, Johnson GA (1977) Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 21: 625–636Google Scholar
  22. 22.
    Ludlam CA, Cash JD (1976) Studies on the liberation of thromboglobulin from human platelets in vitro. Br J Haematol 33: 239–247Google Scholar
  23. 23.
    Moore S, Pepper DS, Cash JD (1975) Platelet anti-heparin activity: The isolation and characterization of platelet factor 4 released from thrombin-aggregated washed human platelets and its dissociation into subunits and the isolation of membrane-bound anti-heparin activity. Biochim Biophys Acta 379: 370Google Scholar
  24. 24.
    Mehta P, Mehta J, Ostrowski N, Brigmon L (1983) Inhibitory effects of diltiazem on platelet activation caused by ionophore A23187 plus ADP or epinephrine in subthreshold concentrations. J Lab Clin Med 102: 332–339Google Scholar
  25. 25.
    Winther K, Naesh O (1987) Platelet alpha-adenoceptor function and aging. Thromb Res 46: 677–684Google Scholar
  26. 26.
    DeClerck F (1986) Blood platelets in human essential hypertension (review). Agents Actions 8: 563–580Google Scholar
  27. 27.
    Steele PP, Weily HS, Davies H, Genton E (1973) Platelet function studies in coronary artery disease. Circulation 48: 1194–1199Google Scholar
  28. 28.
    Mehta J, Mehta P, Lawson DL, Ostrawski N, Brigmon L (1985) Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: Evidence for synthesis of prostacyclin by leucocytes from platelet-derived endoperoxides. J Lab Clin Med 106: 246–255Google Scholar
  29. 29.
    Rodemarker M, Thomas RHM, Kirkby JD, Kovacs IB (1988) Effect of the calcium channel blocker nifedipine on haemostasis, clotting and thrombolysis ex vivo. Thromb Haemost 58: 174Google Scholar
  30. 30.
    Winther K, Knudsen JB, Gormsen J, Jensen J (1986) Effect of metoprolol and propranolol on platelet aggregation and cAMP level in hypertensive patients. Eur J Clin Pharmacol 29: 561–564Google Scholar
  31. 31.
    Hansen KW, Klysner R, Geisler A, Knudsen JB, Glaeser S, Gormsen J (1982) Platelet aggregation and beta-blockers. Lancet 1: 224–225Google Scholar
  32. 32.
    The Norwegian Multicenter Study Group (1981) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801–807Google Scholar
  33. 33.
    Johannesen K-A, Nordrehaug JE, von der Lippe G (1987) Increased occurrence of left ventricular thrombi during early treatment with timolol in patients with acute myocardial infarction. Circulation 75: 151–155Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • H. Sengeløv
    • 1
  • K. Winther
    • 2
  1. 1.Medical Department CBispebjerg HospitalDenmark
  2. 2.Department of Clinical ChemistryFrederiksberg Hospital and Hvidovre HospitalCopenhagenDenmark

Personalised recommendations